Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts.
J Opioid Manag. 2024 Jul-Aug;20(4):339-346. doi: 10.5055/jom.0827.
Opioid use disorder (OUD) can be effectively treated with buprenorphine maintenance. Recent changes in federal policy have removed the requirement for physicians to complete additional training to apply for a Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine. At that time, few primary care providers (PCPs) had completed the training for a DEA waiver to prescribe buprenorphine. Our goal was to identify addressable barriers that may persist despite updates to federal legislation.
A 42-item survey was distributed to 662 physicians and nurse practitioners at two academic medical centers with 100 respondents.
The survey was sent via email and administered anonymously through SurveyMonkey.
All participants were PCPs, and all PCPs at the two academic medical centers were eligible to participate.
PCPs responded to the survey by answering questions online.
PCPs answered questions regarding previous buprenorphine waiver training status, local OUD prevalence, the effectiveness of OUD treatment modalities, and previous barriers to training.
Respondents were compared using descriptive statistics and logistic regression. Of the 100 respondents (response rate: 15 percent), 69 percent had not completed the training. Ninety-nine percent of PCPs agreed that OUD was an issue in their area, 94 percent saw patients with OUD, and 91 percent rated buprenorphine maintenance as a very effective treatment for OUD. Previously waivered and nonwaivered providers did not differ in their responses to these questions. Those who had been waivered were less likely to say they did not see enough patients with OUD to justify training (odds ratio [OR] 0.267, p = 0.005) and were less likely to express concern about allowing patients with OUD into their practice (OR 0.348, p = 0.020) than PCPs who had applied for the DEA waiver.
Despite nonwaivered PCPs recognizing OUD's prevalence, they were concerned about allowing patients with OUD into their practice and said there were not enough patients to justify training. This suggests that attitudinal barriers are the most appropriate target for current intervention.
阿片类药物使用障碍(OUD)可以通过丁丙诺啡维持治疗有效治疗。最近联邦政策的变化取消了医生获得药物管制局(DEA)豁免以开具丁丙诺啡的额外培训要求。当时,很少有初级保健提供者(PCP)完成了开具丁丙诺啡的 DEA 豁免培训。我们的目标是确定尽管联邦立法有所更新,但仍可能存在的可解决的障碍。
一项 42 项的调查分发给了两家学术医疗中心的 662 名医生和护士从业者,其中有 100 名受访者。
该调查通过电子邮件发送,并通过 SurveyMonkey 匿名管理。
所有参与者均为 PCP,且这两家学术医疗中心的所有 PCP 均有资格参与。
PCP 通过在线回答问题来完成调查。
PCP 回答了有关先前丁丙诺啡豁免培训状况、当地 OUD 流行率、OUD 治疗方式的有效性以及先前培训障碍的问题。
使用描述性统计和逻辑回归比较了受访者。在 100 名受访者(应答率:15%)中,69%的人没有完成培训。99%的 PCP 认为他们所在地区存在 OUD 问题,94%的人看到了患有 OUD 的患者,91%的人认为丁丙诺啡维持治疗是治疗 OUD 的非常有效的方法。以前获得豁免和未获得豁免的提供者在回答这些问题时没有差异。获得豁免的提供者表示,他们没有看到足够多的 OUD 患者来证明培训是合理的(比值比[OR] 0.267,p = 0.005),并且他们对允许 OUD 患者进入他们的实践表示关注的可能性较小(OR 0.348,p = 0.020),而那些申请 DEA 豁免的 PCP。
尽管非豁免 PCP 认识到 OUD 的流行,但他们对允许 OUD 患者进入他们的实践表示关注,并表示没有足够的患者来证明培训是合理的。这表明态度障碍是当前干预的最适当目标。